The effects of mesterolone, a male sex hormone in depressed patients (a double blind controlled study).
Based on computer EEG (CEEG) profiles, in high doses, antidepressant properties of mesterolone, a synthetic androgen, were predicted. In a double-blind placebo controlled study, the clinical effects of 300-450 mg daily mesterolone were investigated in 52 relatively young (age range 26-53 years, mean 42.7 years) male depressed outpatients. During 6 weeks of mesterolone treatment, there was a significant improvement of depressive symptomatology. However, since an improvement was also established during the placebo treatment, no statistically appreciable difference in the therapeutic effects of mesterolone was established compared to placebo. Mesterolone treatment significantly decreased both plasma testosterone and protein bound testosterone levels. Patients with high testosterone levels prior to treatment seem to have had more benefit from mesterolone treatment than patients with low testosterone levels. The degree of improvement weakly correlated to the decrease of testosterone levels during mesterolone treatment.
D000328:Adult; D002986:Clinical Trials as Topic; D003866:Depressive Disorder / Q000188:drug therapy*; D013196:Dihydrotestosterone / Q000031:analogs & derivatives*; D004311:Double-Blind Method; D004569:Electroencephalography; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D008655:Mesterolone / Q000009:adverse effects / Q000627:therapeutic use*; D008875:Middle Aged; D008995:Monoamine Oxidase / Q000097:blood; D011569:Psychiatric Status Rating Scales; D013739:Testosterone / Q000097:blood
D013196:Dihydrotestosterone; D008655:Mesterolone; D013739:Testosterone; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D008995:Monoamine Oxidase